Neurogene (NGNE) 10-Q 1 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 01, 2019
Document and Entity Information [Abstract]
Document Type	10-Q
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Registrant Name	AQUINOX PHARMACEUTICALS, INC
Entity Central Index Key	0001404644
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Trading Symbol	AQXP
Title of 12(b) Security	Common Stock
Entity Address, State or Province	DE
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		23,537,368

Condensed consolidated balance

Condensed consolidated balance sheets - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents (Note 3)	$ 72,700	$ 76,928
Receivables, prepayments and deposits	509	237
Total current assets	73,209	77,165
Property and equipment, net	318	400
Operating lease right-of-use asset (Note 2(i))	186
Long-term prepayments and deposits	30	53
Total assets	73,743	77,618
Current liabilities
Accounts payable and other liabilities	958	4,627
Operating lease liability (Note 5)	201
Total current liabilities	1,159	4,627
Other liabilities (Note 4)	2	319
Non-current operating lease liability (Note 5)	253
Total liabilities	1,414	4,946
Share capital: (Note 6)
Common stock
Additional paid-in capital	304,625	302,759
Accumulated deficit	(232,296)	(230,087)
Total stockholders' equity	72,329	72,672
Total liabilities and stockholders' equity	$ 73,743	$ 77,618

Condensed consolidated balanc_2

Condensed consolidated balance sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	23,537,368	23,537,368
Common stock, shares outstanding	23,537,368	23,537,368

Condensed consolidated statemen

Condensed consolidated statements of operations and comprehensive (loss) income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue (Note 8)		$ 25,000		$ 25,000
Operating expenses
Research and development (Note 7)	$ (1,995)	17,996	$ (1,891)	28,504
General and administrative (Note 7)	2,423	4,314	4,978	8,623
Total operating expenses	428	22,310	3,087	37,127
(Loss) income from operations	(428)	2,690	(3,087)	(12,127)
Other income, net (Note 9)	427	228	878	422
Net (loss) income	$ (1)	$ 2,918	$ (2,209)	$ (11,705)
Net (loss) earnings per common stock (Note 10)
Basic		$ 0.12	$ (0.09)	$ (0.50)
Diluted		$ 0.12	$ (0.09)	$ (0.50)
Weighted average number of common stock outstanding (Note 10)
Basic	23,537,368	23,521,719	23,537,368	23,501,351
Diluted	23,537,368	23,846,256	23,537,368	23,501,351
Comprehensive (loss) income:
Net (loss) income	$ (1)	$ 2,918	$ (2,209)	$ (11,705)
Other comprehensive income - unrealized gain on available-for-sale securities		22		68
Comprehensive (loss) income	$ (1)	$ 2,940	$ (2,209)	$ (11,637)

Condensed consolidated statem_2

Condensed consolidated statements of cash flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating activities
Net loss	$ (2,209)	$ (11,705)
Non-cash items:
Stock-based compensation (Note 6(c))	1,866	2,825
Unrealized foreign exchange loss and others	155	322
Changes in operating assets and liabilities:
Receivable, prepayments and deposits	(246)	(174)
Accounts payable and other liabilities	(3,792)	2,324
Cash used in operating activities	(4,226)	(6,408)
Investing activities
Proceeds from maturity of investments		53,000
Purchase of property and equipment		(69)
Cash provided by investing activities		52,931
Financing activities
Proceeds from exercise of stock options		602
Payment on finance lease obligations	(4)	(8)
Cash (used in) provided by financing activities	(4)	594
Effect of exchange rate changes on cash and cash equivalents	2	(19)
Net change in cash and cash equivalents during the period	(4,228)	47,098
Cash and cash equivalents, beginning of period	76,928	52,032
Cash and cash equivalents, end of period	72,700	99,130
Supplemental disclosure of cash flow information:
Interest received	$ 880	$ 736

Condensed consolidated statem_3

Condensed consolidated statements of stockholders' equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Beginning balance at Dec. 31, 2017	$ 98,887		$ 297,459	$ (198,502)	$ (70)
Beginning balance, shares at Dec. 31, 2017		23,472,430
Options exercised	602		602
Options exercised, shares		64,938
Stock-based compensation (Note 6(c))	2,825		2,825
Other comprehensive income	68				68
Net (loss) income	(11,705)			(11,705)
Ending balance at Jun. 30, 2018	90,677		300,886	(210,207)	(2)
Ending balance, shares at Jun. 30, 2018		23,537,368
Beginning balance at Mar. 31, 2018	85,825		298,974	(213,125)	(24)
Beginning balance, shares at Mar. 31, 2018		23,492,161
Options exercised	399		399
Options exercised, shares		45,207
Stock-based compensation (Note 6(c))	1,513		1,513
Other comprehensive income	22				22
Net (loss) income	2,918			2,918
Ending balance at Jun. 30, 2018	90,677		300,886	(210,207)	$ (2)
Ending balance, shares at Jun. 30, 2018		23,537,368
Beginning balance at Dec. 31, 2018	$ 72,672		302,759	(230,087)
Beginning balance, shares at Dec. 31, 2018	23,537,368	23,537,368
Options exercised, shares	0
Stock-based compensation (Note 6(c))	$ 1,866		1,866
Net (loss) income	(2,209)			(2,209)
Ending balance at Jun. 30, 2019	$ 72,329		304,625	(232,296)
Ending balance, shares at Jun. 30, 2019	23,537,368	23,537,368
Beginning balance at Mar. 31, 2019	$ 71,542		303,837	(232,295)
Beginning balance, shares at Mar. 31, 2019		23,537,368
Options exercised, shares	0
Stock-based compensation (Note 6(c))	$ 788		788
Net (loss) income	(1)			(1)
Ending balance at Jun. 30, 2019	$ 72,329		$ 304,625	$ (232,296)
Ending balance, shares at Jun. 30, 2019	23,537,368	23,537,368

Nature of operations

Nature of operations	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of operations	1. Nature of operations Aquinox Pharmaceuticals, Inc. and its subsidiary, Aquinox Pharmaceuticals (Canada) Inc., (consolidated, the “Company”) is a pharmaceutical company discovering and developing novel therapeutics for conditions marked by inflammation, inflammatory pain, and blood cancers. In June 2018, the Company announced that its Phase 3 Leadership 301 clinical trial evaluating once-daily, oral rosiptor for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) failed to meet its primary endpoint. As a result, all further development activities with rosiptor were halted. In July 2018, the Company announced a restructuring plan to reduce operating costs and better align the Company’s workforce with the needs of its business. In November 2018, the Company’s Board of Directors approved further restructuring to reduce operating costs. As of the date of this report, the Company does not have any product candidates in clinical development or identified for clinical development. The Company is currently evaluating strategic options. Aquinox Pharmaceuticals, Inc. was originally incorporated under the name of Aquinox Pharmaceuticals (USA) Inc. on May 31, 2007 Aquinox Pharmaceuticals (Canada) Inc. (“AQXP Canada”) was originally incorporated under the name of 6175813 Canada Inc. on December 26, 2003 The Company operates in Vancouver, British Columbia, Canada.

Condensed summary of significan

Condensed summary of significant accounting policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Condensed summary of significant accounting policies	2. Condensed summary of significant accounting policies (a) Basis of presentation The accompanying unaudited condensed consolidated financial statements are presented in United States (“U.S.”) dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, these consolidated financial statements do not include all of the information and footnotes required for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on March 7, 2019. In management’s opinion, the unaudited condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position as of June 30, 2019, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year. (b) Use of estimates and assumptions The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring management estimates include valuation of stock options, amortization and depreciation, accrual of expenses, valuation allowance for deferred income taxes, and contingencies. Actual results could differ from those estimates. (c) Leases At contract inception, the Company determines if the contract is a lease or contains a lease. Operating leases are recorded as operating lease right-of-use assets, operating lease liabilities and non-current operating lease liabilities. Right-of-use assets and lease liabilities are recognized on the lease commencement date based on the estimated present value of lease payments over the lease term. To determine the present value of the lease payments, the Company utilizes its estimated incremental borrowing rate based on information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The right-of-use assets are recorded net of any lease incentives received. For leases of office space, the Company has elected to not separate the lease components from the non-lease components. (d) Accounting for stock-based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The cost of such award will be recognized over the period during which services are provided in exchange for the award, generally the vesting period. The Company accounts for forfeitures as they occur. All share-based payments to employees are recognized in the consolidated financial statements based upon their respective grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. This approximation uses assumptions regarding a number of inputs that requires management to make significant estimates and judgments. Prior to the completion of the Company’s initial public offering in March 2014, the Company’s common stock was not publicly traded. As a result, the expected volatility assumption is based on industry peer information due to insufficient trading history of the Company’s common stock. Additionally, because the Company has no significant history to calculate the expected term, the simplified method calculation is used. (e) Restructuring costs The Company accounts for restructuring costs in accordance with ASC 420, Exit or Disposal Cost Obligations. ASC 420 specifies that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred, except for a liability where employees are required to render service until they are terminated in order to receive termination benefits and will be retained to render service beyond the minimum retention period. A liability for such one-time termination benefits shall be measured initially at the communication date based on the fair value of the liability as of the termination date and recognized ratably over the future service period. The charges that the Company expects to incur in connection with the restructuring are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the restructuring plan. (f) Revenue recognition The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements subject to the scope of Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and identifies performance obligations that are distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when (or as) the performance obligation is satisfied. The Company’s only source of revenue was amounts earned under a license and collaboration agreement entered into and subsequently terminated in 2018. (g) Segment reporting The Company operates in one segment, the development of novel therapeutics for conditions marked by inflammation, inflammatory pain and blood cancers. The Company has significant Canadian operations but its assets are mostly held in the United States with an immaterial amount of long lived assets in Canada. (h) Net (loss) earnings per common stock Basic net (loss) earnings per common stock is computed by dividing net (loss) earnings by the weighted-average number of common stock outstanding during the period. Diluted net (loss) earnings per common stock is determined using the weighted-average number of common stock outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. (i) Recently issued and recently adopted accounting standards The Company adopted ASU 2016-02 “Leases (Topic 842)” effective January 1, 2019. ASU 2016-02 requires lessees to recognize right-of-use assets and lease liabilities for those leases with a lease term of greater than 12 months. The Company used a modified retrospective approach and elected to use the optional transition method to recognize a cumulative-effect adjustment to the opening balance of retained deficit on January 1, 2019. Consequently, comparative periods will continue to be accounted for in accordance with the current lease standard (Topic 840) and the disclosures will be in accordance with ASC 840. The Company elected to apply the “package of practical expedients”, which permits it not to reassess under ASU 2016-02 its previous conclusions about lease identification, lease classification and initial direct costs and the practical expedient to not separate non-lease components from the associated lease component for the lease of office space. The adoption of ASU 2016-02 resulted in the recognition of right-of-use assets of $0.2 million and lease liabilities of $0.5 million and derecognition of the deferred rent liability of $0.3 million for the Company’s operating leases in the consolidated balance sheets and did not have a material impact to the Company’s consolidated statements of operations or cash flows. The Company adopted ASU 2018-13 “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” on January 1, 2019. ASU 2018-13 eliminated, added and modified certain disclosure requirements for fair value measurements. The disclosure of the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy were eliminated, but disclosures for Level 3 fair value measurements were modified and added to. The adoption of ASU 2018-13 did not have a material impact on the Company’s consolidated financial statements.

Cash and cash equivalents

Cash and cash equivalents	6 Months Ended
	Jun. 30, 2019
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	3. Cash and cash equivalents (in thousands) JUNE 30, 2019 DECEMBER 31, 2018 Cash $ 23,032 $ 25,061 Cash equivalents 49,668 51,867 $ 72,700 $ 76,928

Other liabilities

Other liabilities	6 Months Ended
	Jun. 30, 2019
Other Liabilities Disclosure [Abstract]
Other liabilities	4. Other liabilities (in thousands) JUNE 30, 2019 DECEMBER 31, 2018 Finance lease obligations $ 2 $ 6 Deferred rent liability — 313 $ 2 $ 319

Operating lease liability

Operating lease liability	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Operating lease liability	5. Operating lease liability (a) ASU 2016-02 Leases disclosures The Company has a lease agreement for approximately 10,946 square feet of office space in Canada which commenced on November 1, 2016 and expires October 31, 2021, with the option to extend the lease to October 31, 2026. On December 22, 2016, the Company signed a lease agreement for an additional 2,500 square feet of office space in Canada. The lease for the additional 2,500 square feet expires June 30, 2019. In addition to the basic rent, the Company is obligated to pay for taxes, operating costs, utilities, additional services and other amounts. The components of the lease expense were as follows: (in thousands) THREE MONTHS ENDED JUNE 30, 2019 SIX MONTHS ENDED JUNE 30, 2019 Operating lease cost $ 31 $ 62 Variable lease cost 42 90 Total net lease cost $ 73 $ 152 Supplemental cash flow information related to leases was as follows: (in thousands) THREE MONTHS ENDED JUNE 30, 2019 SIX MONTHS ENDED JUNE 30, 2019 Cash paid for amounts included in the measurement of operating lease liabilities $ 55 $ 96 Operating lease liabilities arising from obtaining right-of-use assets — 515 The calculation of the present value of the lease payments utilized a discount rate of 6% and did not include the option to extend the lease to October 31, 2026. At June 30, 2019, the future payments under the Company’s operating lease liability were as follows: (in thousands) AMOUNT June 30, 2020 $ 206 June 30, 2021 209 June 30, 2022 70 Total undiscounted lease payments 485 Less: imputed interest (31 ) Total operating lease liability 454 Less: current portion (201 ) Non-current operating lease liability – June 30, 2019 $ 253 (b) Disclosures related to periods prior to adoption of ASU 2016-02 Leases The lease agreements contain scheduled rent increases, rent holidays and tenant improvement allowance. As such, the Company has recorded a deferred rent liability of $0.3 million as at December 31, 2018. The minimum lease payments under the non-cancelable operating leases as at December 31, 2018 are payable in the following amounts over the following years. 2019 2020 2021 Total Operating lease obligations $ 362 $ 336 $ 280 $ 978 $ 362 $ 336 $ 280 $ 978 During the three and six months ended June 30, 2018, the Company incurred operating lease costs of $0.2 million and $0.4 million, respectively.

Stockholders' equity

Stockholders' equity	6 Months Ended
	Jun. 30, 2019
Federal Home Loan Banks [Abstract]
Stockholders' equity	6. Stockholders’ equity (a) Share capital Aquinox Pharmaceuticals, Inc. is authorized to issue two classes of stock, common and preferred. The total number of shares Aquinox Pharmaceuticals, Inc. is authorized to issue is 55,000,000 shares, comprised of 50,000,000 common stock and 5,000,000 preferred stock both with a par value of $0.000001 per share. As of June 30, 2019 and December 31, 2018, the total number of shares of common stock issued and outstanding was 23,537,368. As of June 30, 2019 and December 31, 2018, no shares of preferred stock were issued or outstanding. (b) Stock option plan On January 27, 2014, the Company’s stockholders approved the 2014 Equity Incentive Plan (“2014 Plan”). The 2014 Plan became effective on March 6, 2014. The 2014 Plan is the successor to and continuation of the Joint Canadian Stock Option Plan (the “2006 Plan”). No further grants will be made under the 2006 Plan. The 2014 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of equity awards to employees, directors, and consultants. As at June 30, 2019, the maximum number of shares of common stock that may be issued under the 2014 Plan was 4,725,551 shares. Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year for a period of up to 10 4 Stock option transactions and the number of stock options outstanding are summarized below: NUMBER OF SHARES WEIGHTED AVERAGE EXERCISE PRICE WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE (IN YEARS) AGGREGATE INTRINSIC VALUE (IN THOUSANDS) Outstanding at December 31, 2018 2,897,294 $ 9.04 7.96 $ — Options forfeited (266,197 ) 11.76 Outstanding at June 30, 2019 2,631,097 $ 8.76 7.60 $ — Exercisable as of June 30, 2019 1,160,663 $ 11.58 6.01 $ — There were no stock options granted or exercised during the three and six months ended June 30, 2019. (c) Stock-based compensation The fair value of stock options granted is estimated using the Black-Scholes option pricing model with the following weighted average assumptions: THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2019 2018 2019 2018 Expected volatility NA 86 % NA 77 % Expected dividends NA 0 % NA 0 % Expected terms (years) NA 6.00 NA 6.00 Risk free rate NA 2.82 % NA 2.74 % Weighted average grant-date fair value of stock options NA $ 9.60 NA $ 10.83 The Company amortizes the fair value of the stock options on a straight-line basis over the applicable requisite service periods of the awards, which is generally the vesting period. Stock-based compensation expense charged to operating expenses was $0.8 million and $1.9 million for the three and six months ended June 30, 2019, respectively and $1.5 million and $2.8 million for the three and six months ended June 30, 2018, respectively. Total unrecognized compensation cost for all stock-based compensation plans was $5.9 million and $15.4 million as of June 30, 2019 and June 30, 2018, respectively, which is expected to be recognized over a weighted-average period of 2.42 years (June 30, 2018 – 3.00 years).

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2019
Restructuring and Related Activities [Abstract]
Restructuring	7. Restructuring In July 2018, the Company’s Board of Directors approved a restructuring plan to reduce operating costs and better align the Company’s workforce with the needs of its business following the June 27, 2018 announcement that its Phase 3 Leadership 301 clinical trial evaluating once-daily, oral rosiptor for the treatment of IC/BPS failed to meet its primary endpoint. The Company has halted all further development activities with rosiptor. Under the restructuring plan, the Company reduced its workforce by 30 employees (approximately 53% of total employees) and closed its office in San Bruno, California. Affected employees are eligible to receive severance payments and outplacement services. $7.4 million related to clinical trial closing costs, contract cancellations, closing of its office in San Bruno, severance payments and other employee-related costs. During the second quarter of 2019, the Company revised its original estimate of aggregate restructuring charges lower by $ 2.0 The following table shows the total amounts incurred and the liability accrued related to the July 2018 restructuring as at June 30, 2019: (in thousands) CLINICAL TRIAL CLOSING COSTS ONE-TIME EMPLOYEE TERMINATION BENEFITS CONTRACT TERMINATION COSTS SAN BRUNO OFFICE CLOSING COSTS TOTAL EXPENSES Amounts accrued as at January 1, 2018 $ — $ — $ — $ — $ — Charges for the year 5,703 1,879 1,108 465 9,155 Revised estimates during the year 41 2 187 5 235 Total restructuring costs expected to be incurred 5,744 1,881 1,295 470 9,390 Amounts paid during the year (2,204 ) (1,881 ) (1,201 ) (470 ) (5,756 ) Amounts accrued as at December 31, 2018 3,540 — 94 — 3,634 Revised estimates during the period (1,935 ) — (16 ) — (1,951 ) Amounts paid during the period (1,552 ) — (78 ) — (1,630 ) Amounts accrued as at June 30, 2019 $ 53 $ — $ — $ — $ 53 On November 6, 2018, the Company’s Board of Directors approved an additional restructuring plan to further reduce operating costs. Under the restructuring plan, the Company reduced its workforce by 16 employees, including its Chief Operating Officer, Mr. Lloyd Mackenzie, effective December 31, 2018. Further reduction of staff may occur in 2019 pending corporate development activities. Affected employees are eligible to receive severance payments and outplacement services. The Company incurred restructuring charges of $1.0 million in 2018 related to one-time termination severance payments and other employee-related costs. Substantially all of these charges were paid as at December 31, 2018. Additional restructuring charges of at least $0.7 million are expected to be incurred in 2019. The following table shows the total amount expected to be incurred and the liability related to the November 2018 restructuring as at June 30, 2019: (in thousands) ONE-TIME EMPLOYEE TERMINATION BENEFITS Total restructuring costs incurred in 2018 $ 984 Amount paid in 2018 (922 ) Amount accrued at December 31, 2018 62 Restructuring costs expected to be incurred in 2019 663 Amount paid during the period ended June 30, 2019 (254 ) Amount accrued at June 30, 2019 (303 ) Amount expected to be incurred in future periods $ 168 Restructuring recoveries of $1.9 million is recorded in research and development expenses and $0.4 million in general and administrative expenses. The majority of the amounts accrued will be paid by September 30, 2019.

License and collaboration agree

License and collaboration agreement	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License and collaboration agreement	8. License and collaboration agreement In May 2018, the Company entered into an exclusive license and collaboration agreement with Astellas US LLC, a subsidiary of Astellas Pharma Inc. (“Astellas”). The Company granted Astellas an exclusive, royalty-bearing license to use, research, develop, manufacture and commercialize the Company’s drug candidate, rosiptor, and related compounds for all human diseases and conditions in Japan and certain other countries in the Asia-Pacific region. The license and collaboration agreement also included an upfront payment of $25.0 million and contractual milestones. The Company determined that its performance obligations under the agreement are the license and transfer of data, ongoing information sharing with Astellas and the material right granted to Astellas to acquire rosiptor at the Company’s cost. The upfront payment of $25.0 million was allocated between each of the performance obligations. On June 27, 2018, the Company announced the Phase 3 trial of rosiptor failed to meet its primary endpoint and that all further development activities with rosiptor would be halted. As such, the Company will have no further performance obligations under the agreement. On September 4, 2018, Astellas provided notice to the Company that it was terminating the exclusive license and collaboration agreement between the Company and Astellas effective March 4, 2019, unless an earlier termination date is agreed to by the parties. On November 8, 2018, the Company entered into an Early Termination Agreement with Astellas to terminate the exclusive license and collaboration agreement between the Company and Astellas effective November 8, 2018. The $25.0 million upfront payment from Astellas is non-refundable and the full amount was recorded as revenue.

Other income, net

Other income, net	6 Months Ended
	Jun. 30, 2019
Other Income and Expenses [Abstract]
Other income, net	9. Other income, net THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, (in thousands) 2019 2018 2019 2018 Interest income $ 436 $ 376 $ 886 $ 624 Foreign exchange losses (9 ) (30 ) (7 ) (31 ) Miscellaneous expenses — (118 ) (1 ) (171 ) $ 427 $ 228 $ 878 $ 422

Net (loss) earnings per common

Net (loss) earnings per common stock	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Net (loss) earnings per common stock	10. Net (loss) earnings per common stock Basic and diluted net (loss) earnings per common stock is computed by dividing net (loss) earnings by the weighted average number of common stock outstanding. For the three and six months ended June 30, 2019, the Company reported a net loss and therefore excluded outstanding stock options to purchase 2,631,097 shares as the effect would have been antidilutive for the periods presented. For the three months ended June 30, 2018, the Company reported net income and therefore included the dilutive effect of 324,537 2,744,109

Financial instruments

Financial instruments	6 Months Ended
	Jun. 30, 2019
Investments, All Other Investments [Abstract]
Financial instruments	11. Financial instruments The carrying amounts of certain of the Company’s financial instruments including cash, cash equivalents, receivables, accounts payable and other liabilities, approximate their fair values because of their nature and/or short maturities. The Company has no financial instruments that are measured at fair value on a recurring basis as of June 30, 2019 and December 31, 2018. The Company had no Level 1, 2 or 3 financial instruments as at June 30, 2019 and December 31, 2018. There were no transfers to/from Level 3 during the three and six months ended June 30, 2019 and the year ended December 31, 2018.

Condensed summary of signific_2

Condensed summary of significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of presentation	(a) Basis of presentation The accompanying unaudited condensed consolidated financial statements are presented in United States (“U.S.”) dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, these consolidated financial statements do not include all of the information and footnotes required for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on March 7, 2019. In management’s opinion, the unaudited condensed consolidated financial statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position as of June 30, 2019, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for a full year.
Use of estimates and assumptions	(b) Use of estimates and assumptions The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring management estimates include valuation of stock options, amortization and depreciation, accrual of expenses, valuation allowance for deferred income taxes, and contingencies. Actual results could differ from those estimates.
Leases	(c) Leases At contract inception, the Company determines if the contract is a lease or contains a lease. Operating leases are recorded as operating lease right-of-use assets, operating lease liabilities and non-current operating lease liabilities. Right-of-use assets and lease liabilities are recognized on the lease commencement date based on the estimated present value of lease payments over the lease term. To determine the present value of the lease payments, the Company utilizes its estimated incremental borrowing rate based on information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The right-of-use assets are recorded net of any lease incentives received. For leases of office space, the Company has elected to not separate the lease components from the non-lease components.
Accounting for stock-based compensation	(d) Accounting for stock-based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The cost of such award will be recognized over the period during which services are provided in exchange for the award, generally the vesting period. The Company accounts for forfeitures as they occur. All share-based payments to employees are recognized in the consolidated financial statements based upon their respective grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. This approximation uses assumptions regarding a number of inputs that requires management to make significant estimates and judgments. Prior to the completion of the Company’s initial public offering in March 2014, the Company’s common stock was not publicly traded. As a result, the expected volatility assumption is based on industry peer information due to insufficient trading history of the Company’s common stock. Additionally, because the Company has no significant history to calculate the expected term, the simplified method calculation is used.
Restructuring costs	(e) Restructuring costs The Company accounts for restructuring costs in accordance with ASC 420, Exit or Disposal Cost Obligations. ASC 420 specifies that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred, except for a liability where employees are required to render service until they are terminated in order to receive termination benefits and will be retained to render service beyond the minimum retention period. A liability for such one-time termination benefits shall be measured initially at the communication date based on the fair value of the liability as of the termination date and recognized ratably over the future service period. The charges that the Company expects to incur in connection with the restructuring are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the restructuring plan.
Revenue recognition	(f) Revenue recognition The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements subject to the scope of Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and identifies performance obligations that are distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when (or as) the performance obligation is satisfied. The Company’s only source of revenue was amounts earned under a license and collaboration agreement entered into and subsequently terminated in 2018.
Segment reporting	(g) Segment reporting The Company operates in one segment, the development of novel therapeutics for conditions marked by inflammation, inflammatory pain and blood cancers. The Company has significant Canadian operations but its assets are mostly held in the United States with an immaterial amount of long lived assets in Canada.
Net (loss) earnings per common stock	(h) Net (loss) earnings per common stock Basic net (loss) earnings per common stock is computed by dividing net (loss) earnings by the weighted-average number of common stock outstanding during the period. Diluted net (loss) earnings per common stock is determined using the weighted-average number of common stock outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents because their inclusion would be anti-dilutive.
Recently issued and recently adopted accounting standards	(i) Recently issued and recently adopted accounting standards The Company adopted ASU 2016-02 “Leases (Topic 842)” effective January 1, 2019. ASU 2016-02 requires lessees to recognize right-of-use assets and lease liabilities for those leases with a lease term of greater than 12 months. The Company used a modified retrospective approach and elected to use the optional transition method to recognize a cumulative-effect adjustment to the opening balance of retained deficit on January 1, 2019. Consequently, comparative periods will continue to be accounted for in accordance with the current lease standard (Topic 840) and the disclosures will be in accordance with ASC 840. The Company elected to apply the “package of practical expedients”, which permits it not to reassess under ASU 2016-02 its previous conclusions about lease identification, lease classification and initial direct costs and the practical expedient to not separate non-lease components from the associated lease component for the lease of office space. The adoption of ASU 2016-02 resulted in the recognition of right-of-use assets of $0.2 million and lease liabilities of $0.5 million and derecognition of the deferred rent liability of $0.3 million for the Company’s operating leases in the consolidated balance sheets and did not have a material impact to the Company’s consolidated statements of operations or cash flows. The Company adopted ASU 2018-13 “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” on January 1, 2019. ASU 2018-13 eliminated, added and modified certain disclosure requirements for fair value measurements. The disclosure of the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy were eliminated, but disclosures for Level 3 fair value measurements were modified and added to. The adoption of ASU 2018-13 did not have a material impact on the Company’s consolidated financial statements.

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	6 Months Ended
	Jun. 30, 2019
Cash and Cash Equivalents [Abstract]
Schedule of Cash and Cash Equivalents	(in thousands) JUNE 30, 2019 DECEMBER 31, 2018 Cash $ 23,032 $ 25,061 Cash equivalents 49,668 51,867 $ 72,700 $ 76,928

Other liabilities (Tables)

Other liabilities (Tables)	6 Months Ended
	Jun. 30, 2019
Other Liabilities Disclosure [Abstract]
Schedule of Other Liabilities	(in thousands) JUNE 30, 2019 DECEMBER 31, 2018 Finance lease obligations $ 2 $ 6 Deferred rent liability — 313 $ 2 $ 319

Operating lease liability (Tabl

Operating lease liability (Tables)	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Schedule of Components of Lease Expense	The components of the lease expense were as follows: (in thousands) THREE MONTHS ENDED JUNE 30, 2019 SIX MONTHS ENDED JUNE 30, 2019 Operating lease cost $ 31 $ 62 Variable lease cost 42 90 Total net lease cost $ 73 $ 152
Supplemental Cash flow Information Related to Leases	Supplemental cash flow information related to leases was as follows: (in thousands) THREE MONTHS ENDED JUNE 30, 2019 SIX MONTHS ENDED JUNE 30, 2019 Cash paid for amounts included in the measurement of operating lease liabilities $ 55 $ 96 Operating lease liabilities arising from obtaining right-of-use assets — 515
Schedule of Company's Operating Lease Liability	At June 30, 2019, the future payments under the Company’s operating lease liability were as follows: (in thousands) AMOUNT June 30, 2020 $ 206 June 30, 2021 209 June 30, 2022 70 Total undiscounted lease payments 485 Less: imputed interest (31 ) Total operating lease liability 454 Less: current portion (201 ) Non-current operating lease liability – June 30, 2019 $ 253
Schedule of Minimum Lease Payments under Non-cancelable Operating Leases	The minimum lease payments under the non-cancelable operating leases as at December 31, 2018 are payable in the following amounts over the following years. 2019 2020 2021 Total Operating lease obligations $ 362 $ 336 $ 280 $ 978 $ 362 $ 336 $ 280 $ 978

Stockholders' equity (Tables)

Stockholders' equity (Tables)	6 Months Ended
	Jun. 30, 2019
Federal Home Loan Banks [Abstract]
Schedule of Stock Option Transactions and Number of Stock Options Outstanding	Stock option transactions and the number of stock options outstanding are summarized below: NUMBER OF SHARES WEIGHTED AVERAGE EXERCISE PRICE WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE (IN YEARS) AGGREGATE INTRINSIC VALUE (IN THOUSANDS) Outstanding at December 31, 2018 2,897,294 $ 9.04 7.96 $ — Options forfeited (266,197 ) 11.76 Outstanding at June 30, 2019 2,631,097 $ 8.76 7.60 $ — Exercisable as of June 30, 2019 1,160,663 $ 11.58 6.01 $ —
Schedule of Weighted Average Assumptions	The fair value of stock options granted is estimated using the Black-Scholes option pricing model with the following weighted average assumptions: THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2019 2018 2019 2018 Expected volatility NA 86 % NA 77 % Expected dividends NA 0 % NA 0 % Expected terms (years) NA 6.00 NA 6.00 Risk free rate NA 2.82 % NA 2.74 % Weighted average grant-date fair value of stock options NA $ 9.60 NA $ 10.83

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2019
Restructuring Plan, July 2018 [Member]
Summary of Total Amount Expected to Be Incurred and Liability	The following table shows the total amounts incurred and the liability accrued related to the July 2018 restructuring as at June 30, 2019: (in thousands) CLINICAL TRIAL CLOSING COSTS ONE-TIME EMPLOYEE TERMINATION BENEFITS CONTRACT TERMINATION COSTS SAN BRUNO OFFICE CLOSING COSTS TOTAL EXPENSES Amounts accrued as at January 1, 2018 $ — $ — $ — $ — $ — Charges for the year 5,703 1,879 1,108 465 9,155 Revised estimates during the year 41 2 187 5 235 Total restructuring costs expected to be incurred 5,744 1,881 1,295 470 9,390 Amounts paid during the year (2,204 ) (1,881 ) (1,201 ) (470 ) (5,756 ) Amounts accrued as at December 31, 2018 3,540 — 94 — 3,634 Revised estimates during the period (1,935 ) — (16 ) — (1,951 ) Amounts paid during the period (1,552 ) — (78 ) — (1,630 ) Amounts accrued as at June 30, 2019 $ 53 $ — $ — $ — $ 53
Restructuring Plan, November 2018 [Member]
Summary of Total Amount Expected to Be Incurred and Liability	The following table shows the total amount expected to be incurred and the liability related to the November 2018 restructuring as at June 30, 2019: (in thousands) ONE-TIME EMPLOYEE TERMINATION BENEFITS Total restructuring costs incurred in 2018 $ 984 Amount paid in 2018 (922 ) Amount accrued at December 31, 2018 62 Restructuring costs expected to be incurred in 2019 663 Amount paid during the period ended June 30, 2019 (254 ) Amount accrued at June 30, 2019 (303 ) Amount expected to be incurred in future periods $ 168

Other income, net (Tables)

Other income, net (Tables)	6 Months Ended
	Jun. 30, 2019
Other Income and Expenses [Abstract]
Schedule of Other Income, Net	THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, (in thousands) 2019 2018 2019 2018 Interest income $ 436 $ 376 $ 886 $ 624 Foreign exchange losses (9 ) (30 ) (7 ) (31 ) Miscellaneous expenses — (118 ) (1 ) (171 ) $ 427 $ 228 $ 878 $ 422

Nature of operations - Addition

Nature of operations - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2019
Entity Information [Line Items]
Date of incorporation	May 31, 2007
Aquinox Pharmaceuticals (Canada) Inc. [Member]
Entity Information [Line Items]
Date of incorporation	Dec. 26, 2003

Condensed summary of signific_3

Condensed summary of significant accounting policies - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019
Significant Accounting Policies [Line Items]
Recognition of right-of-use assets	$ 186
Recognition of lease liabilities	$ 454
Accounting Standards Update 2016-02 [Member]
Significant Accounting Policies [Line Items]
Recognition of right-of-use assets		$ 200
Recognition of lease liabilities		500
Derecognition of deferred rent liability		$ 300

Cash and cash equivalents - Sch

Cash and cash equivalents - Schedule of Cash and Cash Equivalents (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Cash and Cash Equivalents [Abstract]
Cash	$ 23,032	$ 25,061
Cash equivalents	49,668	51,867
Cash and cash equivalents	$ 72,700	$ 76,928

Other liabilities - Schedule of

Other liabilities - Schedule of Other Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Other Liabilities [Abstract]
Finance lease obligations	$ 2	$ 6
Deferred rent liability		313
Other liabilities	$ 2	$ 319

Operating Lease Liability - Add

Operating Lease Liability - Additional Information (Detail) $ in Thousands	Dec. 22, 2016ft²	Nov. 01, 2016ft²	Jun. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)
Lessee, Lease, Description [Line Items]
Present value of lease payments discount rate			6.00%	6.00%
Deferred rent liability					$ 313
Operating lease costs			$ 200	$ 400
Canada [Member]
Lessee, Lease, Description [Line Items]
Square feet of office space leased | ft²	2,500	10,946
Lease agreement, commencement date	Dec. 22, 2016	Nov. 1, 2016
Lease agreement, expiration date	Jun. 30, 2019	Oct. 31, 2021
Lease agreement extended period		Oct. 31, 2026

Operating Lease Liability - Sch

Operating Lease Liability - Schedule of Components of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Lessee Disclosure [Abstract]
Operating lease cost	$ 31	$ 62
Variable lease cost	42	90
Total net lease cost	$ 73	$ 152

Operating Lease Liability - Sup

Operating Lease Liability - Supplemental Cash flow Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Capital Leases, Net Investment in Direct Financing and Sales Type Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 55	$ 96
Operating lease liabilities arising from obtaining right-of-use assets		$ 515

Operating Lease Liability - S_2

Operating Lease Liability - Schedule of Company's Operating Lease Liability (Detail) $ in Thousands	Jun. 30, 2019USD ($)
Operating lease liability
June 30, 2020	$ 206
June 30, 2021	209
June 30, 2022	70
Total undiscounted lease payments	485
Less: imputed interest	(31)
Total operating lease liability	454
Less: current portion	(201)
Non-current operating lease liability - June 30, 2019	$ 253

Operating Lease Liability - S_3

Operating Lease Liability - Schedule of Minimum Lease Payments under Non-cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2018USD ($)
Lessee Disclosure [Abstract]
2019	$ 362
2020	336
2021	280
Total	$ 978

Stockholders' equity - Addition

Stockholders' equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Equity [Abstract]
Total number of shares authorized	55,000,000		55,000,000
Common stock, shares authorized	50,000,000		50,000,000		50,000,000
Common stock, par value	$ 0.000001		$ 0.000001		$ 0.000001
Preferred stock, shares authorized	5,000,000		5,000,000
Preferred stock, par value	$ 0.000001		$ 0.000001
Common stock, shares issued	23,537,368		23,537,368		23,537,368
Common stock, shares outstanding	23,537,368		23,537,368		23,537,368
Preferred stock, shares issued	0		0		0
Preferred stock, shares outstanding	0		0		0
Maximum number of shares of common stock that may be issued	4,725,551		4,725,551
Shares of common stock reserved for issuance description			Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year for a period of up to 10 years, beginning on January 1, 2015 and ending on and including January 1, 2024, by 4% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the board of directors.
Shares of common stock reserved for issuance percentage			4.00%
Years of increase in shares of common stock reserved for issuance			10 years
Options granted, Number of Shares	0		0
Options exercised, Number of Shares	0		0
Stock-based compensation expense	$ 0.8	$ 1.5	$ 1.9	$ 2.8
Unrecognized stock-based compensation cost	$ 5.9	$ 15.4	$ 5.9	$ 15.4
Unrecognized stock-based compensation cost, weighted-average period recognized			2 years 5 months 1 day	3 years

Stockholders' equity - Schedule

Stockholders' equity - Schedule of Stock Option Transactions and Number of Stock Options Outstanding (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Outstanding, Number of Shares, beginning balance	2,897,294
Options forfeited, Number of Shares	(266,197)
Options Outstanding, Number of Shares, ending balance	2,631,097	2,897,294
Exercisable, Number of Shares, ending balance	1,160,663
Options Outstanding, Weighted Average Exercise Price, beginning balance	$ 9.04
Options forfeited, Weighted Average Exercise Price	11.76
Options Outstanding, Weighted Average Exercise Price, ending balance	8.76	$ 9.04
Exercisable, Weighted Average Exercise Price, ending balance	$ 11.58
Options Outstanding, Weighted Average Remaining Contractual Life (Years), ending balance	7 years 7 months 6 days	7 years 11 months 15 days
Exercisable, Weighted Average Remaining Contractual Life (Years), ending balance	6 years 3 days

Stockholders' equity - Schedu_2

Stockholders' equity - Schedule of Weighted Average Assumptions (Detail) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected volatility	86.00%	77.00%
Expected dividends	0.00%	0.00%
Expected terms (years)	6 years	6 years
Risk free rate	2.82%	2.74%
Weighted average grant-date fair value of stock options	$ 9.60	$ 10.83

Restructuring - Additional Info

Restructuring - Additional Information (Detail) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)EmployeeEmployees
Restructuring Plan, July 2018 [Member]
Restructuring Cost and Reserve [Line Items]
Number of positions eliminated | Employee		30
Number of positions eliminated, period percent		53.00%
Restructuring charges		$ 9,390
Payments for restructuring	$ 1,630	5,756
Revised estimates during the year/ period	(1,951)	235
Restructuring Plan, July 2018 [Member] | One-time Employee Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		1,881
Payments for restructuring		1,881
Revised estimates during the year/ period		2
Restructuring Plan, July 2018 [Member] | Clinical Trial Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		5,744
Payments for restructuring	1,552	2,204
Revised estimates during the year/ period	(1,935)	$ 41
Restructuring Plan, November 2018 [Member]
Restructuring Cost and Reserve [Line Items]
Number of positions eliminated | Employees		16
Restructuring Plan, November 2018 [Member] | One-time Employee Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	663	$ 984
Payments for restructuring	254	$ 922
Research and Development Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring recoveries	1,900
General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 400

Restructuring - Summary of Tota

Restructuring - Summary of Total Amount Expected to Be Incurred and Liability (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Restructuring Plan, July 2018 [Member]
Restructuring Cost and Reserve [Line Items]
Amounts accrued, Beginning balance	$ 3,634
Charges for the year		$ 9,155
Revised estimates during the year/ period	(1,951)	235
Total restructuring costs expected to be incurred		9,390
Amounts paid during the year/ period	(1,630)	(5,756)
Amounts accrued, Ending balance	53	3,634
Clinical Trial Closing Costs [Member] | Restructuring Plan, July 2018 [Member]
Restructuring Cost and Reserve [Line Items]
Amounts accrued, Beginning balance	3,540
Charges for the year		5,703
Revised estimates during the year/ period	(1,935)	41
Total restructuring costs expected to be incurred		5,744
Amounts paid during the year/ period	(1,552)	(2,204)
Amounts accrued, Ending balance	53	3,540
One-time Employee Termination Benefits [Member] | Restructuring Plan, July 2018 [Member]
Restructuring Cost and Reserve [Line Items]
Charges for the year		1,879
Revised estimates during the year/ period		2
Total restructuring costs expected to be incurred		1,881
Amounts paid during the year/ period		(1,881)
One-time Employee Termination Benefits [Member] | Restructuring Plan, November 2018 [Member]
Restructuring Cost and Reserve [Line Items]
Amounts accrued, Beginning balance	62
Total restructuring costs expected to be incurred	663	984
Amounts paid during the year/ period	(254)	(922)
Amounts accrued, Ending balance	(303)	62
Amount expected to be incurred in future periods	168
Contract Termination Costs [Member] | Restructuring Plan, July 2018 [Member]
Restructuring Cost and Reserve [Line Items]
Amounts accrued, Beginning balance	94
Charges for the year		1,108
Revised estimates during the year/ period	(16)	187
Total restructuring costs expected to be incurred		1,295
Amounts paid during the year/ period	$ (78)	(1,201)
Amounts accrued, Ending balance		94
San Bruno Office Closing Costs [Member] | Restructuring Plan, July 2018 [Member]
Restructuring Cost and Reserve [Line Items]
Charges for the year		465
Revised estimates during the year/ period		5
Total restructuring costs expected to be incurred		470
Amounts paid during the year/ period		$ (470)

License and collaboration agr_2

License and collaboration agreement - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2018
Agreement Terms			The license and collaboration agreement also included an upfront payment of $25.0 million and contractual milestones.
Revenue	$ 25,000	$ 25,000	$ 25,000
Non Refundable Up Front Payment Received			25,000
Astellas US LLC [Member]
Revenue			$ 25,000

Other income, net - Schedule of

Other income, net - Schedule of Other Income Net (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Other Income and Expenses [Abstract]
Interest income	$ 436	$ 376	$ 886	$ 624
Foreign exchange losses	(9)	(30)	(7)	(31)
Miscellaneous expenses		(118)	(1)	(171)
Total Other income (expenses)	$ 427	$ 228	$ 878	$ 422

Net (loss) earnings per commo_2

Net (loss) earnings per common stock - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Antidilutive securities excluded from the computation of basic and diluted net loss per share - outstanding stock options	2,631,097		2,631,097	2,744,109
Dilutive shares issued upon the exercise of stock options		324,537

Financial instruments - Additio

Financial instruments - Additional Information (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Transfers to/from Level 3	$ 0	$ 0
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value of Financial instruments	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value of Financial instruments	0	0
Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value of Financial instruments	0	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value of Financial instruments	$ 0	$ 0